Table 1 Baseline characteristics of healthy participants with dyslipidemia

From: Targeting the angiopoietin-like protein 3/8 complex with a monoclonal antibody in patients with mixed hyperlipidemia: a phase 1 trial

 

Pooled placebo (n = 12)

LY3475766

10 mg IV (n = 6)

30 mg IV (n = 6)

100 mg SC (n = 6)

300 mg SC (n = 12)

600 mg SC (n = 6)

Age (years)

52 (20, 65)

44 (25, 61)

50 (31, 62)

56 (30, 60)

52 (33, 65)

51 (31, 58)

Male sex (%)

75

100

100

50

67

67

BMI (kg m−2)

29.5 (25.1, 37.1)

33.4 (26.7, 36.4)

27.1 (21.5, 37.0)

29.3 (26.0, 37.5)

30.5 (24.9, 38.5)

31.4 (25.8, 36.5)

Triglycerides (mg dl−1)

194 (143, 331)

229 (156, 292)

143 (97, 213)

160 (128, 300)

196 (124, 429)

176 (159, 234)

LDL-C (mg dl−1)

142 (94, 197)

139 (85, 186)

134 (68, 179)

155 (98, 219)

138 (97, 263)

145 (102, 237)

HDL-C (mg dl−1)

41 (28, 64)

41 (37, 45)

38 (26, 57)

52 (42, 71)

46 (32, 64)

45 (35, 70)

Non-HDL-C (mg dl−1)

178 (116, 215)

181 (112, 219)

153 (87, 202)

175 (121, 278)

179 (130, 293)

164 (122, 265)

Remnant cholesterol (mg dl−1)

26 (18, 48)

30 (23, 54)

21 (10, 25)

24 (16, 59)

31 (25, 86)

22 (15, 36)

ApoA-I (mg dl−1)

119 (99, 154)

129 (106, 136)

92 (80, 151)

153 (124, 191)

146 (116, 190)

NA

ApoB (mg dl−1)

123 (93, 152)

119 (77, 149)

106 (63, 142)

111 (81, 169)

130 (97, 209)

116 (104, 188)

ApoC-III (mg dl−1)

13 (11, 20)

13 (12, 17)

10 (7, 14)

12 (8, 18)

14 (10, 29)

16 (11, 19)

  1. Unless otherwise indicated, data are given as median (minimum, maximum). BMI, body mass index; IV, intravenous; NA, not available; SC, subcutaneous.
Back to article page